Bariatric Surgery for Morbid Obesity: Risks and Benefits in Chronic Kidney Disease Patients

Advances in Chronic Kidney Disease

Volumn 13, Issue 4, 2006, Pages 403-417

  Zalesin, Kerstyn C ^a   McCullough, Peter A ^a  

^a Divisions of Cardiology   (United States)

Author keywords

Bariatric surgery; chronic kidney disease; diabetes; metabolic syndrome; microalbuminuria; obesity; weight loss

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; METFORMIN; RIMONABANT; TETRAHYDROLIPSTATIN;

ARTICLE; BARIATRIC SURGERY; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COMORBIDITY; DIABETES MELLITUS; DISEASE COURSE; DYSLIPIDEMIA; GLUCOSE TRANSPORT; HAZARD ASSESSMENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INFLAMMATION; METABOLIC SYNDROME X; MICROALBUMINURIA; MORBID OBESITY; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOLOGY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

ALBUMINURIA; BARIATRIC SURGERY; COMORBIDITY; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; JEJUNOILEAL BYPASS; METABOLIC SYNDROME X; OBESITY, MORBID; PERIOPERATIVE CARE; RENAL INSUFFICIENCY, CHRONIC; RISK ASSESSMENT; RISK FACTORS; WEIGHT LOSS;

EID: 33749430996     PISSN: 15485595     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ackd.2006.07.008     Document Type: Article

References (154)

1. Mokdad A.H., Bowman B.A., Ford E.S., et al. The continuing epidemic of obesity and diabetes in the United states. JAMA 286 (2001) 1195-1200
2. Sjostrom L.V. Mortality of severely obese subjects. Am J Clin Nutr 55 (1992) 516S-S523
3. Koplan J.P., and Dietz W.H. Caloric imbalance and public health policy. JAMA 282 (1999) 1579-1581
4. Coresh J., Longenecker J.C., Miller E.R., et al. Epidemiology of cardiovascular risk factors in chronic renal disease. J Am Soc Nephrol 9 (1998) S24-S30
5. US Renal Data System. Annual Data Report: Atlas of End-Stage Renal Disease in the United States (2002), National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD
6. Fox C.S., Larson M.G., Leip E.P., et al. Predictors of new-onset kidney disease in a community based population. JAMA 291 (2004) 844-850
7. Iseki K., Ikemiya Y., Kinjo K., et al. Body mass index and the risk of development of end-stage renal disease in a screened cohort. Kidney Int 65 (2004) 1870-1876
8. Adelman R.D. Obesity and renal disease. Curr Opin Nephrol Hypertens 11 (2002) 331-335
9. Coresh J., Astor B.C., Greene T., et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 41 (2003) 1-12
10. Go A.S., Chertow G.M., Fan D., et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Eng J Med 351 (2004) 1296-1305
11. US Renal Data System. USRDS 2004 Annual Data report. Am J Kidney Dis 45 (2005) 8-280
12. Chagnac A., Weinstein T., and Herman M. The effects of weight loss on renal function in patients with severe obesity. J Am Soc Nephrol 14 (2003) 1480-1486
13. Weisinger J.R., Keempson R.L., Eldridge F.L., et al. The nephrotic syndrome: A complication of massive obesity. Ann intern Med 81 (1974) 440-447
14. O'Donnell M.P., Kasiske B.L., Cleary M.P., et al. Effects of genetic obesity on renal structure and function in the zucker rat II Micropuncture studies. J Lab Clin Med 106 (1985) 605-610
15. Kambham N., Markowitz G.S., and Vealeeri A.M. Obesity related glomerulopathy: An emerging epidemic. Kidney Int 59 (2001) 1498-1809
16. Praga M., Hernandez E., Morales E., et al. Clinical features and long term outcome of obesity associated focal segmental glomerulosclerosis. Nephrol Dial Transplant 16 (2001) 1790-1798
17. Hall J.E. Mechanisms of abnormal renal sodium handling in obesity hypertension. Am J Hypertension 10 (1997) S49-S55
18. Chagnac A., Weinstein T., Korzets A., et al. Glomerular hemodynamics in severe obesity. Am J Physiol Renal Physiol 278 (2000) F817-F822
19. Adelman R.D., Restaino I.G., Alon U.S., et al. Proteinuria and focal segmental glomerulosclerosis in severely obese adolescents. J Pediatr 138 (2001) 481-485
20. Hall J.E., Kuo J.J., Silva A., et al. Obesity, hypertension and renal disease. Curr Opin Nephrol Hypertens 12 (2003) 195-200
21. Hall J.E., Hildebrandt D.A., and Kou J. Obesity hypertension: Role of leptin and sympathetic nervous system. Am J Hypertens 14 (2001) 103S-115S
22. Wolf G., Hamann A., Han D.C., et al. Leptin stimulates proliferation and TGF-β expression in renal glomerular endothelial cells: Potential role in glomerulosclerosis. Kidney Int 56 (1999) 860-872
23. Tuck M.L. Obesity, the sympathetic nervous system, and essential hypertension. Hypertension 19 suppl (1992) I-67-I-77
24. Steinberg H.O., Chaker H., Leaming R., et al. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. Clin Invest 97 (1996) 2601-2610
25. Alpert M.A., and Hashimi M.W. Obesity and the heart. Am J Med Sci 306 (1993) 117-123
26. Hall J.E., Brands M.W., Henegar J.R., et al. Abnormal kidney function as a cause and consequences of obesity hypertension. Clin Exp Pharmacol Physiol 25 (1998) 58-64
27. Vupputuri S., and Sandler D.P. Lifestyle risk factors and chronic kidney disease. Ann Epidemiol 13 (2003) 712-720
28. Fox C.S., Larson M.G., Leip E.P., et al. Predictors of new-onset kidney disease in a community based population. JAMA 291 (2004) 844-850
29. Stengel B., Tarver-Carr M.E., Powe N.R., et al. Lifestyle factors, obesity and the risk of chronic kidney disease. Epidemiology 14 (2003) 479-487
30. Fox C.S., Larson M.G., Leip E.P., et al. Predictors of new-onset kidney disease in a community based population. JAMA 291 (2004) 844-850
31. Tozawa M., Iseki K., Iseki C., et al. Influence of smoking and obesity on the development of proteinuria. Kidney Int 62 (2002) 956-962
32. Bonet E., Deprele C., Sassolas A., et al. Excessive body weight as a new independent risk factor for clinical and pathological progression in primary IgA nephritis. Am J Kidney Dis 37 (2001) 720-727
33. Praga M., Hernández E., Herrero J.C., et al. Influence of obesity on the appearance of proteinuria and renal insufficiency after unilateral nephrectomy. Kidney Int 58 (2000) 2111-2118
34. Nelson R.G., Knowler W.C., Petit D.J., et al. Kidney disease in diabetes, in Diabetes America, National Institutes of Health Publication No. 95-1468. (ed 2). (1995), National Institutes of Health, Bethesda, MD 349-400
35. Hsu C., Bates D.W., and Kuperman G.J. Diabetes, hemoglobinA1c, cholesterol and risk of moderate chronic renal insufficiency in ambulatory population. Am J Kidney Dis 36 (2000) 272-281
36. Jones D.W., Kim J.S., Andrew M.E., et al. Body mass index and blood pressure in Korean men and women: The Korean national blood pressure survey. J Hypertens 12 (1994) 1433-1437
37. Cooper R.S., Potimi C.N., and Ward R. The puzzle of hypertension in African Americans. Sci Am 280 (1999) 56-63
38. Najjar M., Rowland M., and National Center for Health Statistic. Anthropometric reference data and prevalence of overweight: United States, 1976/80 (1987), Government Printing Office, Washington, DC Department of Health and Human Services publication No. (PHS) 87-1688
39. Hall J.E., Brands M.W., and Henegar J.R. Mechanisms of hypertension and kidney disease in obesity. Ann NY Acad Sci 892 (1999) 91-107
40. Kramer H., Luke A., Bidania A., et al. Obesity and prevalent and incident CKD: The hypertension detection and follow-up program. Am J Kidney Dis 46 (2005) 587-594
41. Garrison R.J., Kannel W.B., Stokes M.E., et al. Incidence and precursors of hypertension in young adults: The Framingham offspring study. Prev Med 16 (1987) 235-251
42. El-Atat F., Aneja A., Mcfarlane S., et al. Obesity and hypertension. Endocrinol Metab Clin North Am 32 (2003) 832-854
43. Toto R.D. Treatment of hypertension in chronic kidney disease. Semin Nephrol 25 (2005) 435-439
44. Chobanian A.V., Bakris G.L., Black H.R., et al., The national high blood pressure education program coordinating committee. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 42 (2003) 1206-1252
45. Wright J.T., Bakris G., and Greene T. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease. Results from the AASK trial. JAMA 288 (2002) 2421-2431
46. Adler A.I., Stratton I.M., Neil H.A., et al. Association of systolic blood pressure with macrovascular and microvascular complicatons of type 2 diabetes. (UKPDS 36): Prospective observational study. BMJ 321 (2000) 412-419
47. Miller W.M., Nori Janosz K.E., Yanez J., et al. Effects of weight loss and pharmacotherapy on inflammatory markers of cardiovascular disease. Expert Rev Cardiovasc Ther 3 (2005) 743-759
48. King H., Aubert R.E., and Herman W.H. Global burden of diabetes, 1995-2025: Prevalence, numerical estimates, and projections. Diabetes Care 21 (1998) 1414-1431
49. Brancati F.L., Whelton P.K., Randall B.L., et al. Risk of End-stage renal disease in diabetes mellitus: A prospective cohort study of men screened for MRFIT. JAMA 278 (1997) 2069-2074
50. Hu G., Qiao Q., Tuomilehto J., et al., DECODE Study Group. Prevalence of the metabolic syndrome on mortality from coronary heart disease and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med 164 (2004) 1066-1076
51. Keane W.F., and Eknoyan G. Proteinuria, albuminuria, risk assessment, detection, elimination (PARADE): A position paper of the National Kidney Foundation. Am J Kidney Dis 33 (1999) 1004-1010
52. American Diabetes Association. Diabetic nephropathy. Diabetes Care 25 suppl 1 (2002) 585-589
53. Hovind P., Rosing P., Tarnow L., et al. Remission and regression in the nephropathy of type 1 diabetes when blood pressure is controlled aggressively. Kidney Int 60 (2001) 277-283
54. Gaede P., Vedel P., Larsen N., et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348 (2003) 383-393
55. Diabetes Control and Complication Trial Research: The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 (1993) 977-986
56. Steffes M.W., Chavers B.M., Molitch M.E., et al. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephrolpathy: The Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 290 (2003) 2159-2167
57. Nori Janosz K.E., Miller W.M., Odom J., et al. Optimal diabetes management during medical weight loss for cardiovascular risk reduction. Expert Rev Cardiovasc Ther 3 (2005) 761-775
58. Keane W.F. Lipids and the kidney. Kidney Int 46 (1994) 910-920
59. Muntner P., Coresh J., Smith J.C., et al. Plasma lipids and risk of developing renal dysfunction: The atherosclerosis risk in communities study. Kidney Int 58 (2000) 293-301
60. Klaht S., Levey A.S., Beck G.J., et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. N Engl J Med 330 (1994) 877-884
61. Diamond J.R. Analogous pathobiologic mechanisms is glomerulosclerosis and atherosclerosis. Kidney Int 39 (1991) S29-S34
62. Stepniakkowski K.T., Goodfriend T.L., and Egan B.M. Fatty acids enhance vascular α-adrenergic sensitivity. Hypertension 25 (1995) 774-778
63. Kasiske B.L., O'Donnell M.P., and Keane W.F. The Zucker rat model of obesity, insulin resistance, hyperlipidemia and renal injury. Hypertension 19 (1992) SI110-SI115
64. Fried L.F., Orchard T.J., and Kasiske B.L. Effect of lipid reduction on the progression of renal disease: A meta-analysis. Kidney Int 59 (2001) 260-269
65. Lee T.M., Lin M.S., Tsai C.H., et al. Add on and withdrawal effect of pravastatin on proteinuria in hypertensive patients treated with AT receptor blockers. Kidney Int 68 (2005) 779-789
66. Tonelli M., Sacks F., Pfeffer M., et al. Biomarkers of inflammation and progression of chronic kidney disease. Kidney Int 68 (2005) 237-245
67. Herzog C.A. How to manage the renal patient with coronary heart disease: The agony and the ecstasy of opinion-based medicine. J Am Soc Nephrol 14 (2003) 2556-2572
68. Lakka H.M., Laaksonen D.E., Lakka T.A., et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288 (2002) 2709-2716
69. Chen J., Muntner P., Hamm L.L., et al. The metabolic syndrome and chronic kidney disease in US adults. Ann intern Med 140 (2004) 167-174
70. Kurella M., Lo J.C., and Chertow G.M. Metabolic syndrome and the risk for chronic kidney disease among non diabetic adults. J Am Soc Nephrol 16 (2005) 2134-2140
71. Palaniappan L., Carnethon M., and Fortmann S.P. Association between microalbuminuria and the metabolic syndrome: NHANES III. Am J Hypertens 16 (2003) 952-958
72. Beddhu S., Kimmel P.L., Ramkumar N., et al. Associations of metabolic syndrome with inflammation in CKD: Results from the Third National Health and Nutrition Examination Survey (NHANES). Am J Kidney Dis 46 (2005) 577-586
73. Chen J., Muntner P., Hamm L.L., et al. Insulin resistance and risk of chronic kidney disease in nondiabetic US adults. J Am Soc Nephrol 14 (2003) 469-477
74. Chen J., Muntner P., Hamm L.L., et al. The metabolic syndrome and chronic kidney disease in US adults. Ann intern Med 140 (2004) 167-174
75. Rajala M.W., and Scherer P.E. Minireview: The adipocyte-At the crossroads of energy homostasis, inflammation, and atherosclerosis. Endocrinology 144 (2003) 3765-3773
76. Laaksonen D.E., Niskanen L., Nyyssonen K., et al. C-reactive protein and the development of the metabolic syndrome and diabetes in middle-aged men. Diabetologia 47 (2004) 1403-1410
77. Sorrentino M.J., Pham L., and Ngeyen T. Inflammation and vascular disease: The role for C-reactive peptide. J Geriatr Cardiol 1 (2004) 17-20
78. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 340 (1999) 115-121
79. de Jong P.E., Verhave J.C., and Pint-Sietsma S.J. Obesity and target organ damage: The kidney. Int J Obes Relat Metab Disord 26 (2002) S21-S24
80. Festa A., D'Agoostino Jr. R., Howard G., et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: The Insulin Resistance Atherosclerosis Study (IRAS). Circulation 102 (2000) 42-47
81. Panagiotakos D.B., Pitsasos C., Chrysohoou C., et al. Impact of lifestyle habits on the prevalence of the metabolic syndrome among Greek adults from the ATTICA study. Am Heart J 147 (2004) 106-112
82. Esposito K., Marfella R., Ciotola M., et al. Effect of a Mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: A randomized trial. JAMA 292 (2004) 1440-1446
83. Sorrentino M.J. Implications of the metabolic syndrome: The new epidemic. Am J Card 96 suppl (2005) 3E-7E
84. Miller W., Franklin B., deJong A., et al. High sensitivity C-reactive protein in the morbidly obese: Risk predictor or reflection of adeposity and reconditioning?. 2005 ACSM Annual Meeting, Nashville, Tenn. Med Sci Sports 37 suppl (2005) 5
85. Yudkin J.S. Hyperinsulinemia, insulin resistance, microalbuminuria and the risk of coronary heart disease. Ann Med 28 (1996) 433-438
86. Wesson D.E., Kurtzman N.A., and Prommer J.P. Massive obesity and nephrotic proteinuria with normal renal biopsy. Nephron 40 (1985) 235-237
87. Brenner B.M. Hemodynamically mediated glomerular injury and the progressive nature of kidney disease. Kidney Int 23 (1983) 647-655
88. Verhaver J.C., Hillage H.L., Burgerhof J.G.M., et al. Sodium intake affects urinary albumin excretion especially in overweight subjects. J Intern Med 256 (2004) 324-330
89. Mykkanen L., Zaccaro D.J., Wagenknecht L.E., et al. Microalbuminuria is associated with insulin resistance in nondiabetic subjects: The insulin resistance atherosclerosis study. Diabetes 47 (1998) 793-800
90. de Zeeuw D., Remuzzi G., Parving H.H., et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 110 (2004) 921-927
91. Grassi G., Seravalle G., Dell'Oro R., et al. Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity and sympathetic drive in obese hypertensive individuals: Results of the CROSS study. J Hypertens 21 (2003) 1761-1769
92. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvasular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Lancet 355 (2000) 253-259
93. Viberti G., Wheeldon N.M., and Microalbumuria reduction with Valsartan (MARVAL) study investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: A blood pressure-independent effect. Circulation 106 (2002) 672-678
94. Chiang B.N., Perlamn L.V., and Epstein F.H. Overweight and hypertension: A review. Circulation 39 (1969) 403-421
95. Gaede P., Vedel P., Larsen N., et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. New Eng J Med 348 (2003) 383-393
96. Fried L.F., Orchard T.J., and Kasiske B.L. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 59 (2001) 260-269
97. Morales E., Angeles V., León M., et al. Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies. Am J Kidney Dis 41 (2003) 319-327
98. Gumbs A.A., Irvin I.M., and Ballantyne G.H. Changes in insulin resistance following bariatric surgery: Role of caloric restriction and weight loss. Obes Surg 15 (2005) 462-473
99. Li Z., Hong K., Saltsman P., et al. Long-term efficacy of soy-based meal replacements vs. and individual diet plan in obese type II DM patients: Relative effects of weight loss, metabolic parameters, and C-reactive protein. Eur J Clin Nutr 59 (2005) 411-418
100. Solerte S.B., Fioravanti M., Schifino N., et al. Effects of diet-therapy on urinary protein excretion albuminuria and real haemodynamic function in obese diabetic patients with overt nephropathy. Int J Obes 13 (1989) 203-211
101. Morales E., Angeles V., León M., et al. Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies. Am J Kidney Dis 41 (2003) 319-327
102. Sorrentino M.J. Implications of the metabolic syndrome: The new epidemic. Am J Card 96 suppl (2005) 3E-7E
103. Morales E., Valero M.A., Leon M., et al. Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies. Am J Kidney Dis 41 (2003) 319-327
104. Praga M., Hernández E., Andres A., et al. Effects of body-weight loss and captopril treatment on proteinuria associated with obesity. Nephron 70 (1995) 35-41
105. Solerte S.B., Fioravanti M., Schifino N., et al. Effects of diet-therapy on urinary protein excretion albuminuria and renal haemodynamic function in obese diabetic patients with overt nephropathy. Int J Obes 13 (1989) 203-211
106. Saiki A., Nagayam D., Ohhira M., et al. Effect of weight loss using formula diet on renal function in obese patients with diabetic nephropathy. Int J Obes 29 (2005) 1115-1120
107. Boyle N.G., Haddad E., Kenny G.P., et al. Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: A meta-analysis of controlled clinical trials. JAMA 286 (2001) 1218-1227
108. Wing R.R., Lair E.H., Bononi P., et al. Caloric restriction per se is a significant factor in improvements in glycemic control and insulin sensitivity during weight loss in obese NIDDM patients. Diabetes Care 17 (1994) 30-36
109. Knowler W.C., Barnett-Connor E., Fowler S.E., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention. N Engl J Med 346 (2002) 393-403
110. Wood P.D., Stefanick M.L., Dreon D.M., et al. Changes in plasma lipids and lipoproteins in overweight men during weight loss through dieting as compared with exercise. N Engl J Med 319 (1988) 1173-1179
111. Sacks F.M., Svetkey L.P., Vollmer W.M., et al. Effects on blood pressure of reduced dietary sodium and the dietary approaches to stop hypertension (DASH) diet. N Engl J Med 344 (2001) 3-10
112. Reaven G., Segal K., Hauptman J., et al. Effects of Orlistat-assisted weight loss in decreasing coronary heart disease risk in patients with syndrome X. Am J Cardiol 87 (2001) 827-831
113. Pi-Sunyer F.X., Arbonne L.J., Heshmati H.M., et al. Effect of Rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients. JAMA 295 (2006) 761-775
114. Dansiger M.L., Gleason J.A., Griffith J.L., et al. Comparison of the Atkins Ornish, Weight Watchers and Zone diets for weight loss and heart disease risk reduction: a randomized trial. JAMA 293 (2005) 43-52
115. Gastrointestinal surgery for severe obesity. NIH Consens Dev Conf Consensus Statement 9, March 25-27, Bethesda, Md, 1991
116. Leavey S.F., Strawderman R.L., Jones C.A., et al. Simple nutritional indicators as independent predictors of mortality in hemodialysis patients. Am J Kidney Dis 31 (1998) 997-1006
117. Leavey S.F., McMullough K., Hecking E., et al. Body Mass index and mortality in healthier as compared with sicker haemodialysis patients: Results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 16 (2001) 2386-2394
118. Kaizu Y., Tsunega T., Sakao T., et al. Overweight as another nutritional risk factor for the long-term survival of non-diabetic hemodialysis patients. Clin Nephrol 50 (1998) 44-50
119. Meier-Kriesche H.U., Arndorfer J.A., and Kaplan B. The impact of body mass index on renal transplant outcomes: A significant independent risk factor for graft failure and patient death. Transplantation 73 (2002) 70-74
120. Maarterre W.F., Hariharan S., First M.R., et al. Gastric bypass in morbidly obese kidney transplant recipients. Clin Transplant 10 (1996) 414-419
121. Newcombe V., Blanch A., Slater G.H., et al. Laparoscopic adjustable gastric banding prior to renal transplantation. Obes Surg 15 (2005) 567-570
122. Weiss H., Nehord H., Labeck B., et al. Organ transplantation and obesity: Evaluation, risks and benefits of therapeutic strategies. Obes Surg 10 (2000) 465-469
123. Alexander J.W., Goodman H.R., Gersin K., et al. Gastric bypass in morbidly obese patients with chronic renal failure and kidney transplant. Transplantation 78 (2004) 469-474
124. Alexander J.W., Goodman H.R., Gersin K., et al. Gastric bypass in morbidly obese patients with chronic renal failure and kidney transplant. Transplantation 78 (2004) 469-474
125. Newcombe V., Blanch A., Slater G.H., et al. Laparoscopic adjustable gastric banding prior to renal transplantation. Obes Surg 15 (2005) 567-570
126. McCullough P.A., Sandberg K.R., Miller W.M., et al. Substantial weight gain during adulthood: The road to bariatric surgery. Prev Cardiol 8 (2005) 155-159
127. Jones K.B. Experience with the Roux-en-Y gastric bypass, and commentary on current trends. Obes Surg 10 (2000) 183-185
128. Maclean L.D., Rhode B.M., Sampalis J., et al. Results of the surgical treatment of obesity. Am J Surg 165 (1993) 155-162
129. Agnani S., Vachharajani V.T., Rohit G., et al. Does treating obesity stabilize chronic kidney disease?. BMC Nephrol 6 (2005) 7-10
130. Flavia S.C., Guillermo H.-S., Copley J.B., et al. Renal failure, glomerulonephritis and morbid obesity: Improvement after rapid weight loss following laparoscopic gastric bypass. Obes Surg 15 (2005) 137-140
131. Chagnac A., Weinstein T., and Herman M. The effects of weight loss on renal function in patients with severe obesity. J Am Soc Nephrol 14 (2003) 1480-1486
132. Knerr I., Horbach C., Pland R., et al. Laparoscopically performed gastric banding in a 13 year-old girl with morbid obesity and end stage renal insufficiency allows lifesaving weight loss and hemodialysis. J Pediatr Endocrinol Metab 16 (2003) 1179-1182
133. White S., Brooks E., Jurikova L., et al. Long term outcomes after gastric bypass. Obes Surg 15 (2005) 155-163
134. Dhabuwala A., Cannan R.J., and Stubbs R.S. Improvements in co-morbidities following weight loss from gastric bypass surgery. Obes Surg 10 (2000) 428-435
135. Buchwald H., Avidor Y., Braunwald E., et al. Bariatric surgery: A systematic review and meta-analysis. JAMA 292 (2004) 1724-1737
136. Sugarman H.J., Wolfe L.G., Sica D.A., et al. Diabetes and hypertension in severe obesity and effects of gastric bypass-induced weight loss. Ann Surg 237 (2003) 751-758
137. Pontiroli A.E., Folli F., Paganelli M., et al. Laparoscopic gastric banding prevents type 2 diabetes and arterial hypertension and induces their remission in morbid obesity: A 4-year case-controlled study. Diabetes Care 28 (2005) 2703-2709
138. Richardson D.W., and Vinik A.I. Metabolic implications of obesity: Before and after gastric bypass. Gastroenterol Clin North Am 34 (2004) 9-24
139. Sjöström L., Lindroos A.K., Peltonene M., et al. Lifestyle, diabetes and cardiovascular risk factor 10 years after bariatric surgery. N Engl J Med 351 (2004) 2683-2693
140. Nordenvall B., Backman L., Burman P., et al. Low-oxalate, low-fat diet in hyperoxaluria patients following jejunoileal bypass. Acta Chir Scand 149 (1983) 89-91
141. Nordenvall B., Bacman L., Larsson L., et al. Effects of calcium, aluminum, magnesium and cholestyramine on hyperoxaluria in patients with jejunoileal bypass. Acta Chir Scand 149 (1983) 93-98
142. Mole D.R., Tomson C.R.V., Mortensen N., et al. Renal complications of jejuno-ileal bypass for obesity. Q J Med 94 (2001) 69-77
143. Lieske J.C., Goldfarb D.S., De Simone C., et al. Use of a probiotic to decrease enteric hyperoxaluria. Kidney Int 68 (2005) 1244-1249
144. Eagle K.A., Berger P.B., Calkins H., et al. ACC/AHA guideline update for perioperative cardiovascular evaluation for noncardiac surgery-executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practical Guidelines (committee to update the 1996 guidelines on perioperative cardiovascular evaluation for noncardiac surgery). Anesth Analg 94 (2002) 1052-1064
145. Pasulda P.S., Bistrian B.R., Benoti P.N., et al. The risks of surgery in obese patients. Ann Intern Med 104 (1986) 540-546
146. Chertow G., Lazarus J.M., Christiansen C.L., et al. Preoperative renal risk stratification. Circulation 95 (1997) 878-884
147. Pischon T., and Sharma A.M. Obesity is a risk factor in renal transplant patients. Nephrol Dial Transplant 16 (2001) 14-17
148. Pedersen T., Eliasen K., and Henriksen E. A prospective study of mortality associated with anesthesia and surgery: Risk indicators of mortality in hospital. Acta Anaesthesiol Scand 34 (1990) 176-182
149. MacKenzie C.R., and Charlson M.E. Assessment of perioperative risk in the patient with diabetes mellitus. Surg Gyncol Obstet 167 (1988) 293-299
150. Clement R., Rousou J.A., Engelman R.M., et al. Perioperative morbidity in diabetics requiring coronary artery bypass surgery. Ann Thorac Surg 46 (1988) 321-323
151. Turney J.H., Marshall D.H., Brownjohn A.M., et al. The evolution of acute renal failure, 1956-1988. Q J Med 74 (1990) 83-104
152. McCullough P.A., Gallagher M.J., Dejong A.T., et al. Cardiorespiratory fitness and short-term complications after bariatric surgery. Chest 130 (2006) 517-525
153. Soto F.C., Guillermo H.S., Copley J.B., et al. Renal failure, glomerulonephritis, and morbid obesity: improvement after rapid weight loss following laparoscopic gastric bypass. Obes Surg 15 (2005) 137-140
154. Rex I.H., Hull D., and Trowbridge P.E. Gastroplasty for morbid obesity after cardiac and renal transplantation. Obes Surg 1 (1991) 439-442